Clinicopathologic analysis of CD10+ and CD10- diffuse large B-cell lymphoma. Identification of a high-risk subset with coexpression of CD10 and bcl-2. Am J Clin Pathol 2001 Aug;116(2):183-90
Date
08/08/2001Pubmed ID
11488064DOI
10.1309/J7RN-UXAY-55GX-BUNKScopus ID
2-s2.0-0034757162 (requires institutional sign-in at Scopus site) 63 CitationsAbstract
We analyzed 53 cases of diffuse large B-cell lymphoma (DLBCL) to determine whether expression of CD10 is a relevant biologic parameter. Tumor morphologic features were assessed semiquantitatively. Bcl-2 protein expression was studied by immunohistochemical analysis. The presence or absence of CD10 by flow cytometry was correlated with clinical and pathologic characteristics. CD10+ (23 cases) and CD10- (30 cases) DLBCLs were indistinguishable based on age, sex, extranodal presentation, B symptoms, clinical stage, morphologic features, or bcl-2 expression. However, cases with a CD10+ phenotype showed a significantly lower rate of complete remission. Cases expressing bcl-2 showed trends toward a lower rate of complete remission and poorer overall survival. Examination of CD10 and bcl-2 interaction revealed that the prognostic effects for both of these antigens were due to a subset of CD10+ bcl-2-positive cases. Compared with cases expressing one or neither of these markers, patients with dual-positive tumors had a poorer complete response rate to initial therapy and strikingly worse overall survival. While CD10+ and CD10- DLBCLs are similar with regard to a variety of clinical and pathologic features, CD10 and bcl-2 coexpressing tumors are an extremely high-risk subset based on response to therapy and overall survival.
Author List
Xu Y, McKenna RW, Molberg KH, Kroft SHAuthor
Steven Howard Kroft MD Chair, Professor in the Pathology department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AdolescentAdult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
Child
Child, Preschool
Female
Flow Cytometry
Humans
Immunohistochemistry
Immunophenotyping
Lymphoma, B-Cell
Lymphoma, Large B-Cell, Diffuse
Male
Middle Aged
Neprilysin
Proto-Oncogene Proteins c-bcl-2
Remission Induction
Survival Rate